Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: An update

Pharmaceuticals

Volumn 3, Issue 1, 2010, Pages 10-18

  Sánchez Borges, Mario ^a   Caballero Fonseca, Fernan ^a   Capriles Hulett, Arnaldo ^a   González Aveledo, Luis ^a  

^a Centro Medico Docente La Trinidad   (Venezuela)

Author keywords

Anaphylaxis; Asthma; Drug reactions; Non steroidal anti inflammatory drugs (NSAIDS); Urticaria and angioedema

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; BETA LACTAM ANTIBIOTIC; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PYRAZOLONE;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; AGE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASEPTIC MENINGITIS; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; BRONCHOSPASM; BULLOUS SKIN DISEASE; CHRONIC ARTHRITIS; CHRONIC DISEASE; CHRONIC URTICARIA; CLINICAL FEATURE; CONTACT DERMATITIS; DELAYED HYPERSENSITIVITY; DESENSITIZATION; DISEASE EXACERBATION; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG USE; ERYTHEMA MULTIFORME; FEVER; FIXED DRUG ERUPTION; FLOW CYTOMETRY; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; INFLAMMATION; INTERMETHOD COMPARISON; INTRACUTANEOUS TEST; ISCHEMIC HEART DISEASE; LARYNX EDEMA; MACULOPAPULAR RASH; MORBIDITY; NEPHRITIS; NOSE POLYP; PAIN; PATCH TEST; PATHOGENESIS; PATIENT CARE; PHOTODERMATOSIS; PHOTOPATCH TEST; PNEUMONIA; PROVOCATION TEST; PRURITUS; RESPIRATORY TRACT ALLERGY; REVIEW; RHINITIS; RHINOSINUSITIS; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

EID: 77951936864     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3010010     Document Type: Review

References (47)

1. Von Geh. Sab-Rath, H. Aus der arztlichen Praxis, Mittleilung Uber Einen Fall von Nebenwirkungen des Aspirin (A case report on the side effects of aspirin). Allergy Asthma Proc. 1990, 11, 249-250.
2. Feldman, M.; MacMahon, A.T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal antiinflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med. 2000, 132, 134-143.
3. Fitzgerald, G.A. Coxibs and cardiovascular disease. N. Engl. J. Med. 2004, 351, 1709-1711.
4. Johansson, S.G.O.; Bieber, T.; Dahl, R.; Friedmann, P.S.; Lanier, B.Q.; Lockey, R.F.; Motala, C.; OrtegaMartell, J.A.; Platts-Mills, T.A.; Ring, J.; Thien, F.; Van Cauwenberge, P.; Williams, H.C. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J. Allergy Clin. Immunol. 2004, 113, 832-836.
5. Erbagci, Z. Multiple NSAID intolerance in chronic idiopathic urticaria is correlated with delayed, pronounced and prolonged autoreactivity. J. Dermatol. 2004, 31, 376-382.
6. Doeglas, H.M. Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. Br. J. Dermatol. 1975, 93, 135-144.
7. Kemp, S.F. Anaphylaxis. A review of 266 cases. Arch. Intern. Med. 1995, 155, 1749-1754.
8. Sanchez-Borges, M.; Capriles-Hulett, A. Atopy is a risk factor for nonsteroidal anti-inflammatory drug sensitivity. Ann. Allergy Asthma Immunol. 2000, 84, 101-106.
9. Strom, B.L.; Carson, J.L.; Lee Morse, M.; Welt, S.L.; Sover, K.A. The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1987, 30, 1142-1148.
10. Kim, S.-H; Park, H.S. Genetic markers for differentiating aspirin-hypersensitivity. Yonsei Med. J. 2006, 47, 15-21.
11. Quiralte, J.; Blanco, C.; Delgado, J.; Ortega, N.; Alcntára, M.; Castillo, R.; Anguita, J.L.; Sáenz de San Pedro, B.; Carrillo, T. Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions. J. Inv. Allergol. Clin. Immunol. 2007, 17, 182-188.
12. Sánchez-Borges, M.; Acevedo, N.; Caraballo, L.; Capriles-Hulett, A.; Caballero-Fonseca, F. Increased Total and Mite-specific IgE in patients with Aspirin-induced Urticaria and Angioedema. J. Investig. Allergol. Clin. Immunol. 2009, in press.
13. Quiralte, J.; Blanco, C.; Castillo, R.; Delgado, J.; Carrillo, T. Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J. Allergy Clin. Immunol. 1996, 98, 678-685.
14. namegr typeauthornamesnameSánchez-Borges/snamex, /xfnameM./fname/namex; /xnamesnameAcevedo/snamex, /xfnameN./fname/namex; /xnamesnameVergara/snamex, /xfnameC./fname/namex; /xnamesnameJimenez/snamex, /xfnameS./fname/namex; /xnamesnameZabner-Oziel/snamex, /xfnameP./fname/namex; /xnamesnameMonzon/snamex, /xfnameA./fname/namex; /xnamesnameCaraballo/snamex, /xfnameL./fname/name/namegr The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. J. Investig. Allergol. Clin. Immunol. 2009, 19, 375-382.
15. Sánchez-Borges, M.; Capriles-Hulet, A.; Caballero-Fonseca, F. Risk of skin reactions when using ibuprofen-based medicines. Expert Opin. Drug Saf. 2005, 4, 837-848.
16. Savin, J.A. Current causes of fixed drug eruption in the UK. Br. J. Dermatol. 2001, 145, 667-668.
17. Mockenhaupt, M.; Kelly, J.P.; Kauffman, D.; Stern, R.S.: SCAR Study Group. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal anti-inflammatory drugs: A multinational perspective. J. Rheumatol. 2003, 30, 2234-2240.
18. Roujeau, J.C.; Bioulac-Sage, P.; Bourseau, C.; Guilleaume, J.C.; Bernard, P.; Lok, C.; Plantin, P.; Claudy, A.; Delavierre, C.; Vaillant, L. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch. Dermatol. 1991, 127, 1333-1338.
19. Pigatto, P.D.; Mozzanica, M.; Bigardi, A.S.; Legori, A.; Valsecchi, R.; Cusano, F.; Tosti, A.; Guarrera, M.; Balato, N.; Sertoli, A. Topical NSAID allergic contact dermatitis-Italian Experience. Contact Dermatitis 1993, 29, 39-40.
20. Bagheri, H.; Lhiaubet, V.; Montastrug, J.L.; Chouini-Lalanne, N. Photosensitivity to ketoprofen: Mechanisms and pharmacoepidemiological data. Drug Saf. 2000, 22, 339-349.
21. Allen, J.N. Drug-induced eosinphilic lung disease. Clin. Chest. Med. 2004, 25, 77-88.
22. Jolles, S.; Sewell, C.; Leighton, C. Drug-induced aseptic meningitis. Diagnosis and management. Drug Safety 2000, 22, 215-226.
23. Brezin, J.H.; Katz, S.M.; Schwartz, A.B.; Chinitz, J.L. Reversible renal failure and nephritic syndrome associated with nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 1979, 301, 1271-1273.
24. Szczeklik, A. The cyclooxygenase theory of aspirin-induced asthma. Eur. Respir. J. 1990, 3, 588-593.
25. Picado, C. The role of cyclooxygenase in acetylsalicylic acid sensitivity. Allergy Clin. Immunol. Int. J. World Allergy Org. 2006, 18, 154-157.
26. Mastalerz, L.; Setkowicz, M.; Sanak, M.; Szczeklik, A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J. Allergy Clin. Immunol. 2004, 113, 771-775.
27. Kowalski, M.L.; Bienkiewicz, B.; Woszcek, G. Diagnosis of pyrazolone drug sensitivity: Clinical history versus skin testing and in vitro testing. Allergy Asthma Proc. 1999, 20, 347-352.
28. Blanca, M.; Perez, E.; Garcia, J.J.; Miranda, A.; Terrados, S.; Vega, J.M.; Suau, R. Angioedema and IgE antibodies to aspirin: A case report. Ann. Allergy 1989, 62, 295-298.
29. Pichler, W.J. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 2003, 139, 683-693.
30. Nizankowska-Mogilnicka, E.; Bochenek, G.; Mastalerz, L.; Swiercznska, M.; Picado, C.; Scadding, G.; Kowalski, M.L.; Setkowicz, M.; Ring, J.; Brockow, K.; Bachert, C.; Wohrl, S.; Dahlen, B.; Szczeklik, A. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007, 62, 1111-1118.
31. De Weck, A.L.; Sanz, M.L.; Gamboa, P.M.; Aberer, W.; Blanca, M.; Correia, S.; Erdrian, S.; Jermann, J.M.; Kanny, G.; Kowalski, M.; Mayorga, L.; Medrala, W.; Merk, A.; Sturm, G.J.; Sainte-Laudy, J.; Schneider, M.S.; Sczczeklik, A.; Weber, J.M.; Wedi, A.; Members of the ENDA Group. Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter study. I. Clinical findings and in vitro diagnosis. J. Investig. Allergol. Clin. Immunol. 2009, 19, 355-369.
32. Gamboa, P.; Sanz, ML.; Caballero, M.R.; Urrutia, I.; Antepara, I.; Esparza, I.; De Weck, A.L. The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin. Exp. Allergy 2004, 34, 1448-1457.
33. Sanz, M.L.; Gamboa, P.; De Weck, A.L. A new combined test with flowcytometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs. Int. Arch. Allergy Immunol. 2005, 136, 58-72.
34. Kowalski, M.L.; Ptasinska, A.; Jedrzejczak, M.; Bienkiewicz, B.; Cieslak, M.; Grzegorczyk, J.; Pawliczak, R.; Dubuske, L. Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive aspirin-sensitive patients identification test (ASPI TEST). Allergy 2005, 60, 1139-1145.
35. Himly, M.; Jahn-Schmid, B.; Pittertschatscher, K.; Bohle, B.; Grubmayr, K.; Ferreira, F.; Ebner, H.; Ebner, C. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J. Allergy Clin. Immunol. 2003, 111, 882-888.
36. De Paramo, B.J.; Gancedo, S.Q.; Cuevas, M.; Camo, I.P.; Martin, J.A.; Cosmes, E.L. Paracetamol (acetaminophen) hypersensitivity. Ann. Allergy Asthma Immunol. 2000, 85, 508-511.
37. Del Pozo, M.D.; Lobera, T.; Blasco, A. Selective hypersensitivity to diclofenac. Allergy 2000, 55, 412-413.
38. Zedlitz, S.; Linzbach, L.; Kauffman, R.; Boehncke, W.H. Reproducible identification of the causative drug of a fixed drug eruption by oral provocation and lesional patch testing. Contact Dermatitis 2002, 46, 352-353.
39. Hasan, T.; Jansen, C.T. Photopatch test reactivity: Effect of photoallergen concentration and UVA dosing. Contact Dermatitis 1996, 34, 383-386.
40. Sánchez-Borges, M. Clinical management of nonsteroidal anti-inflammatory drug hypersensitivity. World Allergy Org. J. 2008, 1, 29-33.
41. Talhari, C.; Laucevicinte, I.; Enderlein, E.; Ruzicka, T.; Homey, B. COX-2 selective inhibitor valdecoxib induces severe allergic skin reactions. J. Allergy Clin. Immunol. 2005, 115, 1089-1090.
42. Hope, A.P.; Woessner, K.A.; Simon, R.A.; Stevenson, D.D. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 2009, 123, 406-410.
43. Global Initiative for Asthma. Revision: GINA report, global strategy for asthma management and prevention. Global Strategy for Asthma Management and Prevention 2006. http://www.ginasthma.org/GuidelineItem.asp?intId=1388/, acessed October 2009.
44. Thomas, M.; Yawn, B.P.; Price, D.; Lund, V.; Mullol, J.; Fokkens, W. On behalf of the Eruopean Position Paper on Rhinosinusitis and Nasal Polyps Group. EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of rhinosinusitis and nasal polyps 2007- A summary. Primary Care Respir. J. 2008, 17, 79-89.
45. Sánchez-Borges, M.; Capriles-Hulett, A.; Caballero-Fonseca, F.; Perez, C.R. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann. Allergy 2001, 87, 201-204.
46. Asero, R. Tolerability of rofecoxib. Allergy 2001, 56, 916-917.
47. Zuberbier, T.; Asero, R.; Bindslev-Jensen, C.; Walter Canonica; Church, M.K.; Gimenea-Arnau, A.M.; Grattan, C.E.H.; Kapp, A.; Maurer, M.; Merk, H.F.; Rogala, B.; Saini, S.; Sanchez-Borges, M.; Schmid-Grendelmeire, P.; Schunemann, H.; Staubach, P.; Vena, G.A.; Wedi, B. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria (Position Paper). Allergy 2009, 64, 1427-1243.